Federal Capture Intelligence

Top HHS research and development in biotechnology contractors (NAICS 541711)

Contract actions: October 1, 2021 – September 10, 2026 Updated September 11, 2026 Department of Health and Human Services agency guide NAICS 541711 · Research and Development in Biotechnology
Latest 12 months
$29.9M
Net obligations · Up $248.7M vs. -$218.8M preceding
Prime contractors
9
With positive obligations in the latest 12 months

Research the HHS federal contracting market for research and development in biotechnology under NAICS 541711. Compare top federal contractors and market share, reported contract obligations and spending trends, funding-office attribution, recent award activity, contract types, competition, and procurement methods, observed contract vehicle usage, and potential recompete research leads.

Contract obligation trends for Research and Development in Biotechnology at the Department of Health and Human Services

Federal records show $567.8M in net obligations across 682 awards in Research and Development in Biotechnology at the Department of Health and Human Services from Oct 1, 2021 through Sep 10, 2026. This market accounts for 0.39% of $145.5B in agency-wide net prime contract obligations over the period shown. Latest 12-month net obligations moved from $218.8M in net deobligations to $29.9M in net obligations. 3 prime contractors accounted for at least 80% of positive obligations in that latest period.

Fiscal-year activity

FY26 is year-to-date through Sep 10, 2026; earlier years show complete fiscal-year totals.

FY26 year-to-date: $21.1M versus −$212.5M through the same date in FY25 (Not comparable).
Net obligations · complete fiscal yearNet obligations · FY26 YTDContract actions
View fiscal-year data table
Fiscal yearNet obligationsContract actionsCoverage
FY2022$123.2M641Complete
FY2023$541.2M416Complete
FY2024$85.9M358Complete
FY2025−$203.7M183Complete
FY2026$21.1M101YTD through Sep 10, 2026

Market at a glance

All reported prime contract awards
All-period net obligations
$567.8M
682 awards · 214 prime contractors
Latest 12-month movement
Not comparable
$29.9M vs. −$218.8M
Leading eight prime share
99.6%
Share held by the eight leading prime contractors in the latest 12 months
View agency share, denominators, and set-aside reporting
Agency context
0.39% of $145.5B in agency-wide net obligations.
Set-aside share when reported
5.4% of 313 awards with reported set-aside status.
Set-aside reporting
17 set aside · 296 no set-aside · 369 not reported

What changed in the last 12 months?

Sep 11, 2025–Sep 10, 2026, compared with Sep 11, 2024–Sep 10, 2025.

Competitive shifts

HOFFMANN-LA ROCHE INC. gained the most market share
26.8%→38.1%+11.3 percentage points
The contractor now ranks #2 by positive obligations, based on 2 reported actions.
HOFFMANN-LA ROCHE INC. had the largest decline in reported obligations
$33.8M→$21.9M−$11.9M
The contractor now ranks #2 by positive obligations and accounts for 38.1% of positive obligations, based on 2 reported actions.
AVITA MEDICAL AMERICAS, LLC recorded the largest net deobligation
$0→−$12.5M−$12.5M
The contractor now is unranked by positive obligations, based on 1 reported action.

Award activity

AVITA MEDICAL AMERICAS, LLC recorded the largest deobligation action
−$12.5MFeb 12, 2026 action
Reported under PIID HHSO100201500028C by BARDA - ASPR / DAAPPO / BARDA DCMA. Award net obligations after the action: $40.8M.
View supporting award

Buyer demand

Reported obligations through NATIONAL INSTITUTES OF HEALTH NICHD decreased
$6.3M→$4.9M−$1.4M
Latest-period activity spans 4 awards across 4 prime contractors.
How these findings are calculated

Findings are selected from matched-period changes in obligations, share, rank, funding offices, concentration, reported set-asides, material award actions, and agency-peer outliers. Related signals are combined, and only material evidence-backed changes are shown. Review the full methodology.

Federal contract obligations by funding office

See how positive obligations were attributed across funding offices in the 12 months ending Sep 10, 2026.

86.0% of positive obligations were attributed to BARDA - ASPR / DAAPPO / BARDA DCMA. That represents $29.9M, up $255.2M from the preceding 12 months.

Latest 12-month share of positive obligations; the gray segment represents all other reported offices.

  1. BARDA - ASPR / DAAPPO / BARDA DCMA86.0% · $29.9M · up $255.2M
  2. NATIONAL INSTITUTES OF HEALTH NICHD14.0% · $4.9M · down $1.4M
  3. All other reported offices0.0100% of positive obligations
View reported office rankings, comparisons, and evidence

USAspending assigns each award to a funding office. That office may differ from the requiring activity, program office, contracting office, individual buyer, or actual customer.

  1. Reported funding office

    BARDA - ASPR / DAAPPO / BARDA DCMA

    #1New to the positive-obligation ranking

    Latest 12 months

    $29.9M

    86.0% of positive obligations

    Versus preceding 12 months

    +$255.2M

    27 active prime contractors · 36 awards

    View office comparison and evidence

    Reported obligations moved from $225.3M in net deobligations to $29.9M in net obligations. The office’s share of positive obligations moved from 0% to 86.0%, a change of +86.0 percentage points.

    The latest period contains 44 actions across 36 awards and 15 newly active prime contractors. The preceding period contained 19 active prime contractors and 33 awards.

    Leading award-level changes

  2. Reported funding office

    NATIONAL INSTITUTES OF HEALTH NICHD

    #2Down 1 from #1

    Latest 12 months

    $4.9M

    14.0% of positive obligations

    Versus preceding 12 months

    −$1.4M

    4 active prime contractors · 4 awards

    View office comparison and evidence

    Reported obligations decreased 22.1% from $6.3M to $4.9M. The office’s share of positive obligations moved from 80.7% to 14.0%, a change of −66.7 percentage points.

    The latest period contains 8 actions across 4 awards and 1 newly active prime contractor. The preceding period contained 4 active prime contractors and 11 awards.

  3. Reported funding office

    NATIONAL INSTITUTES OF HEALTH NINDS

    #3New to the positive-obligation ranking

    Latest 12 months

    $1K

    0% of positive obligations

    Versus preceding 12 months

    +$22K

    1 active prime contractor · 1 award

    View office comparison and evidence

    Reported obligations moved from $20K in net deobligations to $1K in net obligations. The office’s share of positive obligations moved from 0% to 0%, a change of 0.0 percentage points.

    The latest period contains 1 action across 1 award. The preceding period contained 5 active prime contractors and 7 awards.

  4. Reported funding office

    NIH NIAMS

    No positive-obligation rank

    Latest 12 months

    $0

    0% of positive obligations

    Versus preceding 12 months

    +$1K

    0 active prime contractors · 0 awards

    View office comparison and evidence

    Reported obligations moved from $1K in net deobligations to $0 in net obligations. The office’s share of positive obligations moved from 0% to 0%, a change of 0.0 percentage points.

    The latest period contains 0 actions across 0 awards. The preceding period contained 1 active prime contractor and 2 awards.

  5. Reported funding office

    NATIONAL INSTITUTE OF HEALTH NIEHS

    No positive-obligation rank

    Latest 12 months

    $0

    0% of positive obligations

    Versus preceding 12 months

    −$140K

    0 active prime contractors · 0 awards

    View office comparison and evidence

    Reported obligations decreased 100.0% from $140K to $0. The office’s share of positive obligations moved from 1.8% to 0%, a change of −1.8 percentage points.

    The latest period contains 0 actions across 0 awards. The preceding period contained 1 active prime contractor and 1 award.

  6. Reported funding office

    FDA OFFICE OF ACQ GRANT SVCS

    No positive-obligation rank

    Latest 12 months

    −$2K

    0% of positive obligations

    Versus preceding 12 months

    +$544K

    1 active prime contractor · 1 award

    View office comparison and evidence

    Reported obligations narrowed from $546K to $2K in net deobligations. The office’s share of positive obligations moved from 0% to 0%, a change of 0.0 percentage points.

    The latest period contains 1 action across 1 award and 1 newly active prime contractor. The preceding period contained 2 active prime contractors and 2 awards.

  7. Reported funding office

    NATIONAL INSTITUTES OF HEALTH

    No positive-obligation rank

    Latest 12 months

    −$2K

    0% of positive obligations

    Versus preceding 12 months

    +$39K

    1 active prime contractor · 1 award

    View office comparison and evidence

    Reported obligations narrowed from $41K to $2K in net deobligations. The office’s share of positive obligations moved from 0% to 0%, a change of 0.0 percentage points.

    The latest period contains 1 action across 1 award and 1 newly active prime contractor. The preceding period contained 1 active prime contractor and 1 award.

  8. Reported funding office

    NATIONAL INSTITUTES OF HEALTH NIDA

    No positive-obligation rank

    Latest 12 months

    −$355K

    0% of positive obligations

    Versus preceding 12 months

    −$329K

    3 active prime contractors · 9 awards

    View office comparison and evidence

    Reported obligations widened from $25K to $355K in net deobligations. The office’s share of positive obligations moved from 0% to 0%, a change of 0.0 percentage points.

    The latest period contains 9 actions across 9 awards and 2 newly active prime contractors. The preceding period contained 1 active prime contractor and 2 awards.

  9. Reported funding office

    OFC ASST SEC FOR PREPARENESS RES

    No positive-obligation rank

    Latest 12 months

    −$1.4M

    0% of positive obligations

    Versus preceding 12 months

    −$759K

    1 active prime contractor · 1 award

    View office comparison and evidence

    Reported obligations widened from $621K to $1.4M in net deobligations. The office’s share of positive obligations moved from 0% to 0%, a change of 0.0 percentage points.

    The latest period contains 1 action across 1 award and 1 newly active prime contractor. The preceding period contained 1 active prime contractor and 1 award.

  10. Reported funding office

    NATIONAL INSTITUTES OF HEALTH NIAID

    No positive-obligation rank

    Latest 12 months

    −$3.1M

    0% of positive obligations

    Versus preceding 12 months

    −$4.4M

    28 active prime contractors · 49 awards

    View office comparison and evidence

    Reported obligations moved from $1.3M in net obligations to $3.1M in net deobligations. The office’s share of positive obligations moved from 17.2% to 0%, a change of −17.2 percentage points.

    The latest period contains 67 actions across 49 awards and 11 newly active prime contractors. The preceding period contained 23 active prime contractors and 48 awards.

    Leading award-level changes

Contract types, competition, and procurement methods

From Sep 11, 2025 through Sep 10, 2026, 14 awards had positive obligations totaling $58.4M. Np was the leading reported procedure, accounting for 49.2% of positive obligations. Awards with a reported parent IDV accounted for 8.8%. Reported awards used contract vehicles such as Preclinical Models of Infectious Disease and BARDA CRN Animal Model Development.

Leading award type
91.2%
Definitive Contract
Leading reported procedure
49.2%
Np
Reported parent IDV
8.8%
of positive obligations had a reported parent IDV
Median reported offers
2
14 of 14 awards reported offers

Observed contract vehicles

Only exact reported parent-PIID matches are shown; missing parent IDs are not inferred.

Buying method changes

Compared with Sep 11, 2024–Sep 10, 2025. Based on 14 current awards and 30 preceding awards with positive net obligations.

Reported full-and-open obligation share
13.4%
Down from 99.9% in the preceding period
Median positive award obligations
$387K
Up from $140K in the preceding period
How to read these changes

Directional color and the Up or Down labels show historical movement only. Green does not mean favorable and red does not mean unfavorable; neither predicts a future procurement method.

View buying-method details and data coverage

Award types

Reported valueAwardsPositive obligationsShare
Definitive Contract(D)4$53.2M91.2%
Delivery Order(C)10$5.1M8.8%

Reported parent-award types

Reported valueAwardsPositive obligationsShare
IDC(B)10$5.1M8.8%
Not reported4$53.2M91.2%

Single- or multiple-award parent structure

Reported valueAwardsPositive obligationsShare
Multiple Award(M)10$5.1M8.8%
Not reported4$53.2M91.2%

Solicitation procedures

Reported valueAwardsPositive obligationsShare
Np(NEGOTIATED PROPOSAL/QUOTE)2$28.7M49.2%
Br(BASIC RESEARCH)1$21.9M37.4%
Subject to Multiple Award Fair Opportunity(MAFO)9$5.1M8.8%
Negotiated Proposal/Quote(NP)1$2.7M4.6%
Mafo(SUBJECT TO MULTIPLE AWARD FAIR OPPORTUNITY)1$1K0%

Extent competed

Reported valueAwardsPositive obligationsShare
A(FULL AND OPEN COMPETITION)4$50.6M86.6%
Full and Open Competition(A)10$7.8M13.4%

Fair-opportunity and limited-source reporting

Reported valueAwardsPositive obligationsShare
Fair Opportunity Given(FAIR)10$5.1M8.8%
Not reported4$53.2M91.2%

Other-than-full-and-open reasons

Reported valueAwardsPositive obligationsShare
Not reported14$58.4M100.0%

Contract pricing types

Reported valueAwardsPositive obligationsShare
U(COST PLUS FIXED FEE)3$28.7M49.2%
S(COST NO FEE)1$21.9M37.4%
Cost Plus Fixed Fee(U)6$5.4M9.2%
Cost No Fee(S)4$2.5M4.2%

Product or Service Codes

Reported valueAwardsPositive obligationsShare
Health R&d Services; Health Care Services; Applied Research(AN12)4$29.3M50.1%
Health R&d Services; Health Care Services; Experimental Development(AN13)6$26.8M45.9%
Health R&d Services; Health Care Services; Basic Research(AN11)4$2.3M4.0%

Awarding subagencies

Reported valueAwardsPositive obligationsShare
Office of Assistant Secretary for Preparedness and Response(7505)7$50.8M87.0%
National Institutes of Health(7529)7$7.6M13.0%

Awarding offices

Reported valueAwardsPositive obligationsShare
Barda - Aspr / Daappo / Barda Dcma(75A501)7$50.8M87.0%
National Institutes of Health Nichd(75N940)2$5.0M8.5%
National Institutes of Health Niaid(75N930)4$2.6M4.5%
National Institutes of Health Nida(75N950)1$1K0%

Reported parent IDVs

Reported valueAwardsPositive obligationsShare
HHSO100201500004I(7505)1$2.2M3.8%
HHSN272201700040I(7529)2$1.9M3.3%
HHSN272201700032I(7529)1$387K0.66%
HHSN272201300012I(7529)1$318K0.54%
HHSN275201300024I(7529)1$224K0.38%
HHSO100201700011I(7505)3$89K0.15%
HHSN271201600006I(7529)1$1K0%
Not reported4$53.2M91.2%

Exact vehicle-match evidence

Reported award data linked 4 awards to a specific catalog vehicle.

Offers, award size, and timing

Median reported offers
2 median
14 reported · 0 not reported
Positive award obligations
$387K median
$46K–$2.7M middle 50%
Reported performance period
3,094 days (~8.5 years) median
14 reported · 0 not reported

Calculations group latest-period actions by award, retain awards with positive net obligations for share denominators, and use each award's latest reported USAspending procurement fields as of Sep 10, 2026. Blank competition, pricing, PSC, or parent-IDV values remain not reported; they are not inferred. Offer counts must be positive and below the FPDS 999 placeholder. Awarding organizations can differ from the funding agency that defines this page.

Top federal contractors

Latest 12-month market share, concentration, and complete prime contractor rankings across the period shown.

Prime contractor concentration
3 of 9prime contractors account for at least 80% of positive obligations in the last 12 months
Largest prime contractor
41.8%of positive obligations in the last 12 months
Leading four prime contractors
92.3%of positive obligations in the last 12 months
Leading eight prime contractors
99.6%of positive obligations in the last 12 months

Based on $57.4M in positive obligations during the 12 months ending Sep 10, 2026. Individual shares and movement appear in the searchable rankings below. Movement compares with Sep 11, 2024–Sep 10, 2025.

Last 12mo obligation volume: Highest positive obligations first; net deobligations follow by magnitude; contractors with no activity in the last 12 months follow by all-period obligations. Ranks use the complete contractor list and remain fixed when search narrows the results.

15 leading contractors
  1. #1

    Last 12mo obligations

    $24.0M

    41.8%

    Dollar movement

    −$55.9M

    vs. prior 12 months

    Last 12mo awards

    1 award

    1 action

    Historical and award details for EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.
    Obligations: prior → latest
    $79.9M → $24.0M
    −70.0%
    Share: prior → latest
    63.4% → 41.8%
    −21.6 percentage points
    All-period obligations
    $303.2M
    41.8% of all-period positive obligations · 4 awards
    Recorded activity
    Since Nov 18, 2021
    through Aug 18, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside12
    Not reported00
    Reported small business00
    All-period set-aside types

    None reported.

  2. #2

    Last 12mo obligations

    $21.9M

    38.1%

    Dollar movement

    −$11.9M

    vs. prior 12 months

    Last 12mo awards

    1 award

    2 actions

    Historical and award details for HOFFMANN-LA ROCHE INC.
    Obligations: prior → latest
    $33.8M → $21.9M
    −35.3%
    Share: prior → latest
    26.8% → 38.1%
    +11.3 percentage points
    All-period obligations
    $70.7M
    9.8% of all-period positive obligations · 1 award
    Recorded activity
    Since Jun 1, 2022
    through Aug 10, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside11
    Not reported00
    Reported small business00
    All-period set-aside types

    None reported.

  3. #3

    Last 12mo obligations

    $4.7M

    8.3%

    Dollar movement

    −$1.2M

    vs. prior 12 months

    Last 12mo awards

    2 awards

    5 actions

    Historical and award details for THE EMMES COMPANY, LLC
    Obligations: prior → latest
    $6.0M → $4.7M
    −20.7%
    Share: prior → latest
    4.7% → 8.3%
    +3.5 percentage points
    All-period obligations
    $33.0M
    4.6% of all-period positive obligations · 9 awards
    Recorded activity
    Since Nov 18, 2021
    through Sep 2, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside11
    Not reported10
    Reported small business21
    All-period set-aside types

    None reported.

  4. #4

    Last 12mo obligations

    $2.3M

    4.1%

    Dollar movement

    +$334.1M

    vs. prior 12 months

    Last 12mo awards

    2 awards

    2 actions

    Historical and award details for REGENERON PHARMACEUTICALS INC
    Obligations: prior → latest
    −$331.7M → $2.3M
    Not comparable
    Share: prior → latest
    0% → 4.1%
    +4.1 percentage points
    All-period obligations
    −$2.9M
    0% of all-period positive obligations · 3 awards
    Recorded activity
    Since Jun 30, 2022
    through Jul 30, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside22
    Not reported00
    Reported small business00
    All-period set-aside types

    None reported.

  5. #5

    Last 12mo obligations

    $1.9M

    3.3%

    Dollar movement

    +$2.3M

    vs. prior 12 months

    Last 12mo awards

    3 awards

    6 actions

    Historical and award details for UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON
    Obligations: prior → latest
    −$428K → $1.9M
    Not comparable
    Share: prior → latest
    0% → 3.3%
    +3.3 percentage points
    All-period obligations
    $8.4M
    1.2% of all-period positive obligations · 17 awards
    Recorded activity
    Since Nov 2, 2021
    through Aug 25, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside00
    Not reported37
    Reported small business00
    All-period set-aside types

    None reported.

  6. #6

    Last 12mo obligations

    $1.6M

    2.8%

    Dollar movement

    +$762K

    vs. prior 12 months

    Last 12mo awards

    10 awards

    13 actions

    Historical and award details for BATTELLE MEMORIAL INSTITUTE
    Obligations: prior → latest
    $853K → $1.6M
    +89.3%
    Share: prior → latest
    0.68% → 2.8%
    +2.1 percentage points
    All-period obligations
    $10.8M
    1.5% of all-period positive obligations · 34 awards
    Recorded activity
    Since Oct 5, 2021
    through Aug 31, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside00
    Not reported1012
    Reported small business00
    All-period set-aside types

    None reported.

  7. #7

    Last 12mo obligations

    $387K

    0.68%

    Dollar movement

    −$29K

    vs. prior 12 months

    Last 12mo awards

    1 award

    2 actions

    Historical and award details for TRUSTEES OF TUFTS COLLEGE
    Obligations: prior → latest
    $416K → $387K
    −7.0%
    Share: prior → latest
    0.33% → 0.68%
    +0.3 percentage points
    All-period obligations
    $1.3M
    0.18% of all-period positive obligations · 4 awards
    Recorded activity
    Since Dec 21, 2021
    through May 7, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside00
    Not reported12
    Reported small business00
    All-period set-aside types

    None reported.

  8. #8

    Last 12mo obligations

    $310K

    0.54%

    Dollar movement

    −$737K

    vs. prior 12 months

    Last 12mo awards

    2 awards

    3 actions

    Historical and award details for UNIVERSITY OF ALABAMA AT BIRMINGHAM
    Obligations: prior → latest
    $1.0M → $310K
    −70.4%
    Share: prior → latest
    0.83% → 0.54%
    −0.3 percentage points
    All-period obligations
    $3.2M
    0.45% of all-period positive obligations · 10 awards
    Recorded activity
    Since Nov 24, 2021
    through Apr 27, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside00
    Not reported21
    Reported small business00
    All-period set-aside types

    None reported.

  9. #9

    Last 12mo obligations

    $224K

    0.39%

    Dollar movement

    −$78K

    vs. prior 12 months

    Last 12mo awards

    1 award

    2 actions

    Historical and award details for LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
    Obligations: prior → latest
    $302K → $224K
    −25.7%
    Share: prior → latest
    0.24% → 0.39%
    +0.1 percentage points
    All-period obligations
    $5.8M
    0.80% of all-period positive obligations · 5 awards
    Recorded activity
    Since Dec 10, 2021
    through Aug 6, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside00
    Not reported13
    Reported small business00
    All-period set-aside types

    None reported.

  10. #10

    Last 12mo obligations

    −$12.5M

    0%

    Dollar movement

    −$12.5M

    vs. prior 12 months

    Last 12mo awards

    1 award

    1 action

    Historical and award details for AVITA MEDICAL AMERICAS, LLC
    Obligations: prior → latest
    $0 → −$12.5M
    Not comparable
    Share: prior → latest
    0% → 0%
    0.0 percentage points
    All-period obligations
    −$12.5M
    0% of all-period positive obligations · 1 award
    Recorded activity
    Since Nov 30, 2021
    through Feb 12, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside10
    Reported no set-aside00
    Not reported00
    Reported small business10
    All-period set-aside types
    • 1 · Total small business
  11. #11

    Last 12mo obligations

    −$2.6M

    0%

    Dollar movement

    −$2.6M

    vs. prior 12 months

    Last 12mo awards

    1 award

    2 actions

    Historical and award details for PFIZER INC
    Obligations: prior → latest
    $0 → −$2.6M
    Not comparable
    Share: prior → latest
    0% → 0%
    0.0 percentage points
    All-period obligations
    −$2.7M
    0% of all-period positive obligations · 1 award
    Recorded activity
    Since Sep 6, 2023
    through May 12, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside10
    Not reported00
    Reported small business00
    All-period set-aside types

    None reported.

  12. #12

    Last 12mo obligations

    −$2.5M

    0%

    Dollar movement

    −$2.5M

    vs. prior 12 months

    Last 12mo awards

    1 award

    1 action

    Historical and award details for NOVARTIS PHARMACEUTICALS CORPORATION
    Obligations: prior → latest
    $0 → −$2.5M
    Not comparable
    Share: prior → latest
    0% → 0%
    0.0 percentage points
    All-period obligations
    −$14.0M
    0% of all-period positive obligations · 1 award
    Recorded activity
    Since Apr 13, 2022
    through Jul 8, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside10
    Not reported00
    Reported small business00
    All-period set-aside types

    None reported.

  13. #13

    Last 12mo obligations

    −$2.0M

    0%

    Dollar movement

    −$2.0M

    vs. prior 12 months

    Last 12mo awards

    1 award

    1 action

    Historical and award details for ALTASCIENCES PRECLINICAL SEATTLE LLC
    Obligations: prior → latest
    $0 → −$2.0M
    Not comparable
    Share: prior → latest
    0% → 0%
    0.0 percentage points
    All-period obligations
    −$2.0M
    0% of all-period positive obligations · 1 award
    Recorded activity
    Since Jul 21, 2026
    through Jul 21, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside00
    Not reported10
    Reported small business00
    All-period set-aside types

    None reported.

  14. #14

    Last 12mo obligations

    −$1.1M

    0%

    Dollar movement

    −$1.1M

    vs. prior 12 months

    Last 12mo awards

    2 awards

    2 actions

    Historical and award details for ICON GOVERNMENT AND PUBLIC HEALTH SOLUTIONS, INC.
    Obligations: prior → latest
    $0 → −$1.1M
    Not comparable
    Share: prior → latest
    0% → 0%
    0.0 percentage points
    All-period obligations
    −$2.3M
    0% of all-period positive obligations · 6 awards
    Recorded activity
    Since Dec 15, 2021
    through Sep 24, 2025

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside00
    Not reported20
    Reported small business20
    All-period set-aside types

    None reported.

  15. #15

    Last 12mo obligations

    −$1.0M

    0%

    Dollar movement

    −$1.0M

    vs. prior 12 months

    Last 12mo awards

    3 awards

    5 actions

    Historical and award details for FAMILY HEALTH INTERNATIONAL
    Obligations: prior → latest
    $0 → −$1.0M
    Not comparable
    Share: prior → latest
    0% → 0%
    0.0 percentage points
    All-period obligations
    −$1.6M
    0% of all-period positive obligations · 3 awards
    Recorded activity
    Since Jul 12, 2022
    through Aug 12, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside00
    Not reported30
    Reported small business00
    All-period set-aside types

    None reported.

Potential federal contract recompetes

Investigate potential recompetes surfaced by near-term end dates, award value, and recent contract changes.

EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.

EO14042 EMERGENT AV7909 ANTHRAX VACCINE

The reported potential end date is Sep 29, 2026. Current award value is 96.7% of reported potential value ($1.4B of $1.5B).

Performance period

99.5%

As of Sep 10, 2026Potential end Sep 29, 2026

Current award value as a share of potential value

96.7%

$1.4B current$1.5B potential
Supporting data

Reported performance starts Sep 30, 2016.

No later potential end date is reported; current and potential end dates are both Sep 29, 2026.

$1.4B is obligated against $1.4B in current reported award value (100.0%).

Reported potential end dates: May 31, 2025 → Aug 31, 2025 → Sep 29, 2026.

Obligations are compared with current reported award value, not treated as a contract ceiling.

PIID HHSO100201600030C

CERUS CORPORATION

EXTEND THE BASE (CLIN 0001) AND OPTION 1 (CLIN 0002) PERIOD OF PERFORMANCE THROUGH 31 MARCH 2027 TO ALLOW COMPLETION OF THE REMAINING EFFORT WITHOUT INCREASING THE CONTRACT VALUE. TRANSFER GOVERNMENT-FURNISHED EQUIPMENT (GFE) FROM CONTRACT HHSO100201

$185.2M is obligated on an award with a reported potential end date of March 31, 2027.

Performance period

94.9%

As of Sep 10, 2026Potential end Mar 31, 2027

Current award value as a share of potential value

70.0%

$197.5M current$282.2M potential
Supporting data

Reported performance starts Jun 17, 2016.

No later potential end date is reported; current and potential end dates are both Mar 31, 2027.

$185.2M is obligated against $197.5M in current reported award value (93.8%).

Reported potential end dates: Dec 31, 2023 → Dec 31, 2025 → Sep 30, 2026 → Mar 31, 2027.

THE PURPOSE OF THIS MODIFICATION: 1. NO COST EXTENSION FOR OPTION 01 (CLIN 0002), 2. REVISE KEY PERSONNEL, AND 3. REVISE THE STATEMENT OF WORK.

Obligations are compared with current reported award value, not treated as a contract ceiling.

PIID HHSO100201600009C

DNAE GROUP HOLDINGS LIMITED

DNAE / PATHOGEN IDENTIFICATION FROM SPECIMEN, VIA CAPTURE, EXTRACTION AND SEQUENCING (PISCES)

The reported potential end date is Dec 31, 2026. Current award value is 70.1% of reported potential value ($43.4M of $61.9M).

Performance period

97.0%

As of Sep 10, 2026Potential end Dec 31, 2026

Current award value as a share of potential value

70.1%

$43.4M current$61.9M potential
Supporting data

Reported performance starts Sep 28, 2016.

No later potential end date is reported; current and potential end dates are both Dec 31, 2026.

$43.4M is obligated against $43.4M in current reported award value (100.0%).

Reported potential end dates: May 31, 2023 → Sep 15, 2023 → Dec 31, 2024 → Jan 31, 2025 → Dec 31, 2025 → Dec 31, 2026.

Obligations are compared with current reported award value, not treated as a contract ceiling.

PIID HHSO100201600017C

REGENERON PHARMACEUTICALS INC

INMAZEB EBOLA THERAPEUTICS

$695.7M is obligated on an award with a reported potential end date of September 29, 2027.

Performance period

89.5%

As of Sep 10, 2026Potential end Sep 29, 2027

Current award value as a share of potential value

91.7%

$695.7M current$759.1M potential
Supporting data

Reported performance starts Sep 30, 2017.

No later potential end date is reported; current and potential end dates are both Sep 29, 2027.

$695.7M is obligated against $695.7M in current reported award value (100.0%).

Obligations are compared with current reported award value, not treated as a contract ceiling.

PIID HHSO100201700016C

MERCK SHARP & DOHME LLC

MERCK - EBOLA ZAIRE VACCINE

$236.3M is obligated on an award with a reported potential end date of September 27, 2027.

Performance period

89.5%

As of Sep 10, 2026Potential end Sep 27, 2027

Current award value as a share of potential value

81.1%

$236.3M current$291.4M potential
Supporting data

Reported performance starts Sep 28, 2017.

No later potential end date is reported; current and potential end dates are both Sep 27, 2027.

$236.3M is obligated against $236.3M in current reported award value (100.0%).

Obligations are compared with current reported award value, not treated as a contract ceiling.

PIID HHSO100201700012C

THE EMMES COMPANY, LLC

DATA COORDINATING CENTER FOR THE BEST PHARMACEUTICALS FOR CHILDREN ACT

$66.0M is obligated on an award with a reported potential end date of June 28, 2027.

Performance period

92.0%

As of Sep 10, 2026Potential end Jun 28, 2027

Current award value as a share of potential value

94.9%

$66.0M current$69.5M potential
Supporting data

Reported performance starts Jul 28, 2017.

Current performance is reported through May 28, 2027.

$66.0M is obligated against $66.0M in current reported award value (100.0%).

Reported potential end dates: May 28, 2027 → Jun 28, 2027.

Obligations are compared with current reported award value, not treated as a contract ceiling.

PIID HHSN275201700002C

These are research leads, not confirmed recompetes. USAspending records through Sep 10, 2026; reported dates and values can change through later modifications.

Recent federal contract award activity

Recent contract actions with unusually large obligation changes or meaningful shifts in contractor and funding-office activity.

Deobligation

This action

−$12.5M

AVITA MEDICAL AMERICAS, LLC

BARDA - ASPR / DAAPPO / BARDA DCMA

AUTOGRAFT-SPARING PRODUCTS FOR DEFINITIVE CARE OF BURN INJURIES

Why it stands out

The award contracted while office-attributed spending grew overall.

The action removed $12.5M while office-attributed spending rose $255.2M.

Award net obligations
$40.8M
Share of 12-month positive obligations
21.9%
Supporting data
Prime contractor
0% share
$12.5M net decline; action accounted for 100.0%
Funding office
#1 · 86.0% attributed share
$255.2M net increase despite this negative action
Related:Largest deobligation actionLargest net deobligation
PIID HHSO100201500028C · Mod P00017
Deobligation

This action

−$1.4M

PFIZER INC

OFC ASST SEC FOR PREPARENESS RES

THE PURPOSE OF MODIFICATION P00014 IS TO DE-OBLIGATE CANCELING FUNDS

Why it stands out

This award recorded a material contraction.

The action removed $1.4M. A deobligation does not by itself show lower requirement demand.

Award net obligations
$68.4M
Share of 12-month positive obligations
2.4%
Supporting data
Prime contractor
0% share
$2.6M net decline; action accounted for 52.8%
Funding office
0% attributed share
$759K net decline; action exceeded it by $621K
PIID HHSO100201500029C · Mod P00014
Modification

This action

+$24.0M

EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.

BARDA - ASPR / DAAPPO / BARDA DCMA

EO14042 EMERGENT AV7909 ANTHRAX VACCINE

Why it stands out

One action equaled more than a third of the market’s latest 12-month positive obligations.

The $24.0M action represented 41.8% of the market’s positive obligations over the latest 12 months.

Award net obligations
$1.4B
Share of 12-month positive obligations
41.8%
Supporting data
Prime contractor
#1 · 41.8% share
$55.9M net decline despite this positive action
Funding office
#1 · 86.0% attributed share
+86.0 percentage points · $255.2M net increase; action accounted for 9.4%
Related:Unusually large actionLargest deobligation action
PIID HHSO100201600030C · Mod P00021
Deobligation

This action

−$2.5M

NOVARTIS PHARMACEUTICALS CORPORATION

BARDA - ASPR / DAAPPO / BARDA DCMA

THE PURPOSE OF THIS MODIFICATION IS TO DEOBLIGATE CANCELLING FUNDS IN THE AMOUNT OF $2,539,496.23 AS FOLLOWS: 1. $1,050,656.17 FROM CLIN 0013 2. $1,488,840.00 FROM CLIN 0014 3. $0.06 FROM CLIN 0012

Why it stands out

The award contracted while office-attributed spending grew overall.

The action removed $2.5M while office-attributed spending rose $255.2M.

Award net obligations
$16.3M
Share of 12-month positive obligations
4.4%
Supporting data
Prime contractor
0% share
$2.5M net decline; action accounted for 100.0%
Funding office
#1 · 86.0% attributed share
$255.2M net increase despite this negative action
PIID HHSO100201700026C · Mod P00013
Modification

This action

+$13.8M

HOFFMANN-LA ROCHE INC.

BARDA - ASPR / DAAPPO / BARDA DCMA

THE PURPOSE OF THIS MODIFICATION IS ADD SUPPLEMENTAL FUNDING FOR CLIN 0001 & 0002 AND TO UPDATED THE PERIOD OF PERFORMANCE (POP) FOR CLIN 0001 TO END ON 12/31/2026.

Why it stands out

One action equaled about a fifth of the market’s latest 12-month positive obligations.

The $13.8M action represented 24.0% of the market’s positive obligations over the latest 12 months.

Award net obligations
$183.8M
Share of 12-month positive obligations
24.0%
Supporting data
Prime contractor
#2 · 38.1% share
$11.9M net decline despite this positive action
PIID HHSO100201600038C · Mod P00016
Modification

This action

+$2.2M

BATTELLE MEMORIAL INSTITUTE

BARDA - ASPR / DAAPPO / BARDA DCMA

SCREENING POTENTIAL MEDICAL COUNTERMEASURES TO CHLORINE GAS IN A SMALL ANIMAL MODEL.

Why it stands out

The award grew alongside stronger contractor activity.

The modification added $2.2M while contractor obligations rose $762K overall.

Award net obligations
$6.6M
Share of 12-month positive obligations
3.8%
Supporting data
Prime contractor
#6 · 2.8% share
+2.1 percentage points · $762K net increase; action exceeded it by $1.4M
PIID 75A50121F33005 · Mod P00017
View recent award activity by date (10)
  1. SRI INTERNATIONALModification · PIID HHSN27100003
    Action+$1K
    Award net obligations$2.9M
  2. TRANSNETYX, INCDeobligation · PIID 75N94021F00008
    Action−$8K
    Award net obligations$17K
  3. UTAH STATE UNIVERSITYDeobligation · PIID 75N93021F00006
    Action−$191
    Award net obligations$686K
  4. PPD DEVELOPMENT LPDeobligation · PIID 75N93019F00131
    Action−$62K
    Award net obligations$5.7M
  5. DYNPORT VACCINE COMPANY LLCDeobligation · PIID HHSN27200003
    Action−$639
    Award net obligations$1.8M
  6. THE EMMES COMPANY, LLCDeobligation · PIID HHSN275201700002C
    Action−$8K
    Award net obligations$66.0M
  7. AMERICAN TYPE CULTURE COLLECTIONDeobligation · PIID HHSN272201600013C
    Action−$137
    Award net obligations$141.0M
  8. BATTELLE MEMORIAL INSTITUTEDeobligation · PIID 75N93020F00001
    Action−$533K
    Award net obligations$8.5M
  9. COLORADO STATE UNIVERSITYDeobligation · PIID 75N93020F00001
    Action−$70K
    Award net obligations$1.4M
  10. ICAHN SCHOOL OF MEDICINE AT MOUNT SINAIDeobligation · PIID HHSN272201400008C
    Action−$56K
    Award net obligations$79.7M

HHS research and development in biotechnology market FAQs

Answers based on reported federal contract data.

Who are the top HHS research and development in biotechnology contractors?

In the 12 months through September 10, 2026, EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC., HOFFMANN-LA ROCHE INC., and THE EMMES COMPANY, LLC were the leading HHS research and development in biotechnology prime contractors by positive obligations.

  1. #1

    EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.

    $23,983,588 in positive obligations

  2. #2

    HOFFMANN-LA ROCHE INC.

    $21,850,000 in positive obligations

  3. #3

    THE EMMES COMPANY, LLC

    $4,730,377 in positive obligations

Rankings use reported USAspending award data.

How did HHS net obligations change in the research and development in biotechnology market?

HHS net prime contract obligations for research and development in biotechnology under NAICS 541711 changed from -$218,795,632 in the preceding 12 months to $29,925,705 in the 12 months through September 10, 2026. A percentage change is not stated because the preceding value was not positive or the latest value was negative.

Latest 12 months
$29,925,705
Net prime contract obligations
Preceding 12 months
-$218,795,632
Net prime contract obligations
Change
Not comparable
No percentage reported

Reported contract actions, not outlays or a forecast.

What recent HHS contract award activity was reported in the research and development in biotechnology market?

Recent HHS contract award activity reported in the research and development in biotechnology market included actions for AVITA MEDICAL AMERICAS, LLC, PFIZER INC, and EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. during the 12 months through September 10, 2026.

Action obligations are transaction-level amounts, not current award-level obligations.

Which procurement methods were reported for HHS contracts under NAICS 541711?

From September 11, 2025 through September 10, 2026, HHS reported 14 positive-obligation awards for research and development in biotechnology under NAICS 541711. The leading award type was definitive contract. The leading reported procedure was np.

Positive-obligation awards
14
Leading reported procedure
Np
49.2% of positive obligations
Leading award type
Definitive Contract
91.2% of positive obligations
Full and open
13.4%
of positive obligations
Reported parent IDV
8.8%
of positive obligations
Observed vehicles
Preclinical Models of Infectious Disease and BARDA CRN Animal Model Development
Exact matches from reported parent PIIDs

Percentages use positive obligations as the denominator.

Which HHS research and development in biotechnology awards may warrant recompete research?

6 HHS research and development in biotechnology awards may warrant recompete research based on reported potential-end dates, including awards held by EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC., CERUS CORPORATION, and DNAE GROUP HOLDINGS LIMITED.

Research leads, not confirmed recompetes. Dates may change through later modifications.

Apply this research to a live pursuit

Sweetspot connects opportunity qualification, competitive research, capture, and proposal work in one workspace.

See Sweetspot in action

Related market research

Complete market indexes:

Same NAICS at other agencies:

Nearby NAICS at this agency:

Markets sharing leading prime records:

Leading-prime vehicle memberships:

Company memberships do not establish award-channel use.

Reported obligations include contract actions from October 1, 2021 through September 10, 2026. Set-aside and business-size fields reflect award records, not a contractor's current eligibility.

Review data methodology